Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT02170233 Completed - Sepsis Clinical Trials

SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography

Start date: August 2014
Phase:
Study type: Observational

The study aim is to examine point-of-care ultrasound findings, reliability, and ease of performance in association with fluid responsiveness for patients with severe sepsis and septic shock. The investigators propose a prospective observational research study of patients presenting to one of three Yale New Haven Hospital emergency departments, York Street Campus, St. Raphael's Campus, and Shoreline Medical Center who meet criteria for sepsis, severe sepsis or septic shock during their emergency department visit.

NCT ID: NCT02159079 Completed - Sepsis Clinical Trials

A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)

BALANCE
Start date: July 2014
Phase: N/A
Study type: Interventional

Sepsis is a common inflammatory response to infection characterized by hypovolemia and vasodilation for which early administration of intravenous fluids has been suggested to improve outcomes. The ideal fluid balance following initial resuscitation is unclear. Septic patients treated in the intensive care unit commonly receive significant volumes of intravenous fluids with resultant positive fluid balance for up to a week after their initial resuscitation. Observational studies have associated fluid receipt and positive fluid balance in patients with severe sepsis and septic shock with increased mortality but are inherently limited by indication bias. In order to determine the optimal approach to fluid management following resuscitation in patients with severe sepsis and septic shock, a randomized controlled trial is needed. The primary hypothesis of this study is that, compared to usual care, a conservative approach to fluid management after resuscitation in patients with sepsis and cardiopulmonary dysfunction will increase intensive care unit free days.

NCT ID: NCT02157259 Completed - Sepsis Clinical Trials

An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia

SEA050
Start date: December 2013
Phase: N/A
Study type: Observational

This is an observational study to identify the etiology, management, and outcome of community-acquired sepsis and severe sepsis in children and adults in Southeast Asia. The study will take place in Thailand, Vietnam, and Indonesia, the partner countries of SEAICRN. Potential study patients will be any patients (both children and adults) who are presented at the hospital with community-acquired sepsis or severe sepsis and require hospitalization.

NCT ID: NCT02135770 Completed - Clinical trials for Severe Sepsis With Septic Shock

Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis

Start date: January 2013
Phase: Phase 3
Study type: Interventional

Sepsis is a clinical syndrome which infection trigger systemic inflammatory response. Uncontrolled inflammatory process leads to multiple organ dysfunction and cause early mortality in severe sepsis. Unfractionated heparin is an anticoagulant that widely used either for DVT prophylaxis or treatment of disseminated intravascular coagulation. Heparin also have an anti-inflammatory effect through downregulates nuclear factor kappa B and tumor necrosis factor alpha. Aim of this study is to determine effects of low dose unfractionated heparin treatment on inflammation in severe sepsis patient.

NCT ID: NCT02106975 Completed - Sepsis Clinical Trials

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

CITRIS-ALI
Start date: April 2014
Phase: Phase 2
Study type: Interventional

Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

NCT ID: NCT02052895 Completed - Sepsis Clinical Trials

Utility of Presepsin in Distinguishing Between Sepsis and SIRS

Start date: January 2014
Phase:
Study type: Observational

This is an observational study to evaluate the diagnostic accuracy of presepsin levels to discriminate between sepsis and SIRS upon presentation with critical illness compatible with either sepsis or systemic inflammatory response syndrome (SIRS).

NCT ID: NCT02041663 Completed - Septic Shock Clinical Trials

Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis

SAMIRA
Start date: March 5, 2012
Phase: N/A
Study type: Interventional

Use of brain natriuretic peptide to evaluate the cardiac function in the course of meningococcal septic shock or severe sepsis.

NCT ID: NCT02030158 Completed - Clinical trials for Severe Sepsis and Septic Shock

Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock

Start date: January 2015
Phase:
Study type: Observational

This is the statistical analysis plan for an individual patient data meta-analysis (IPDMA) of three EGDT clinical trials.

NCT ID: NCT02026856 Completed - Severe Sepsis Clinical Trials

Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis

Se-AOX
Start date: December 2013
Phase: N/A
Study type: Observational

This study looked at parenteral administration of selenium to septic patients and subsequently monitored dynamic changes of selected activities of antioxidant enzymes and the development of clinical status.

NCT ID: NCT02025699 Completed - Sepsis Clinical Trials

Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis

TailoredT
Start date: February 2014
Phase: N/A
Study type: Observational

The TAILORED-Treatment consortium was established to develop new tools aimed to increase the effectiveness of antibiotic and antifungal therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in children and adults.